The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The following is a summary of “Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study,” published in the ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

Dividend yield and robust drug pipeline are bullish going forward. AbbVie (NYSE:ABBV) shares are plummeting as the company's ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...